Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6884189

CCOC(=O)[C@@H](N)Cc1ccc(Nc2nc3ccccc3n2C)cc1.O=C(O)C(F)(F)F

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.46
RAB9A P51151 5/20 0.46
HDAC6 Q9UBN7 2/20 0.41
CRHR1 P34998 1/20 0.41
DRD2 P14416 1/20 0.41
TBXA2R P21731 1/20 0.41
GAA P10253 1/20 0.40
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
HSD17B10 Q99714 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
BRAF P15056 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL28194120 0.77 ALPI (0.53) TP53
SCHEMBL6887783 0.73 ELANE (0.42) NPC1RAB9AHDAC6DRD2TBXA2R
SCHEMBL132790 0.70 ALPI (0.61) NPC1MEN1TP53KMT2A
SCHEMBL132409 0.70 ALPI (0.61) NPC1MEN1TP53KMT2A
SCHEMBL616963 0.70 ALPI (0.61) NPC1MEN1TP53KMT2A
SCHEMBL9910545 0.70 NPC1 (0.62) NPC1RAB9AHDAC6GAAMAPT
Hydrochloric Acid SCHEMBL1098660 0.69 ALPI (0.59) NPC1MEN1TP53KMT2A
Hydrochloric Acid SCHEMBL216055 0.69 ALPI (0.59) NPC1MEN1TP53KMT2A
Hydrochloric Acid SCHEMBL839857 0.69 ALPI (0.59) NPC1MEN1TP53KMT2A
SCHEMBL7864444 0.69 ALPI (0.59) NPC1MEN1TP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6740654-B2 INHIBIT THE BINDING OF INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS, OR DISORDERS INVOLVING THE INAPPROPRIATE GROWTH OR MIGRATION OF CELLS. CELLTECH R & D LIMITED (GB) 2004-05-25 US disclosed